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ω-Transaminases for the amination of
functionalised cyclic ketones
N. Richter,a,b R. C. Simon,c H. Lechner,c W. Kroutil,b,c J. M. Wardd and H. C. Hailes*a
The potential of a number of enantiocomplementary ω-transaminases (ω-TAms) in the amination of cyclic
ketones has been investigated. After a preliminary screening of several compounds with increasing com-
plexity, diﬀerent approaches to shift the equilibrium of the reaction to the amine products were studied,
and reaction conditions (temperature and pH) optimised. Interestingly, 2-propylamine as an amine donor
was tolerated by all ﬁve selected ω-TAms, and therefore used in further experiments. Due to the higher
conversions observed and interest in chiral amines studies then focused on the amination of α-tetralone
and 2-methylcyclohexanone. Both ketones were aminated to give the corresponding amine with at least
one of the employed enzymes. Moreover, the amination of 2-methylcyclohexanone was investigated in
more detail due to the diﬀerent stereoselectivities observed with TAms used. The highest yields and
stereoselectivities were obtained using the ω-TAm from Chromobacterium violaceum (CV-TAm), produ-
cing 2-methylcyclohexylamine with complete stereoselectivity at the (1S)-amine position and up to 24 : 1
selectivity for the cis : trans [(1S,2R) : (1S,2S)] isomer.
Introduction
Single isomer chiral amines are one of the most common func-
tional groups found in natural products and pharmaceutical
compounds including, sitagliptin the antihyperglycemic drug
for the treatment of diabetes,1 the antihypertensive dilevalol,2
and (S)-rivastigmine used for the treatment of Alzheimer’s
disease.3,4 Enantiopure amines are therefore highly desirable
building blocks for the development of new pharmaceuticals.
The frequent occurrence of such chiral amines has also high-
lighted interest in their preparation as synthons for use in the
pharmaceutical sector. For instance, the aminotetraline motif
is present in a variety of pharmaceuticals, such as the anti-
depressants sertraline and norsertraline with an α-amino-
teraline core,5–7 and rotigotine a treatment for Parkinson’s
disease containing a β-aminotetraline core unit.8,9
Traditionally single isomer chiral amines are generated
from racemic mixtures using crystallisation methods, or they
can be synthesised using chiral auxiliaries.7,10–12 In addition
more recently a variety of organocatalytic, metal-dependent as
well as chemo-enzymatic dynamic kinetic resolution methods
have been developed to produce enantiopure amines.13–15 The
requirement for metals in some of these systems such as
lipase-catalysed dynamic kinetic resolutions is however a
major backdraw when considering the sustainability of the
process.14 An alternative method to generate enantiopure
amines that is currently attracting significant interest is the
use of ω-transaminases (ω-TAms).16–20 Despite the improved
sustainability with this biocatalytic approach, one problem has
been the issue of shifting the reaction equilibrium towards the
amine product. However, in recent years eﬀorts have been
focussed on the development of methods to overcome this
unfavourable equilibrium, via the chemical or enzymatic
removal of the co-product or use of an excess of amine
donor.1,21–30 The incorporation of enzymatic cascades has
been particularly successful, including reuse of the co-product
in a multi-enzymatic cascade with a carboligation step.31
Several of these studies used ω-TAms for the preparation of
pharmaceutical intermediates or bioactive compounds,24,25,27–36
and have also lead to an industrial process.1
Here we describe the use of several ω-TAms in the asym-
metric amination of several cyclic substrates. Moreover,
diﬀerent methods to shift the equilibrium towards the desired
amine product were compared and reaction parameters opti-
mised with the model compound cyclohexanone 1. The amin-
ation of two selected substrates was then investigated in
further detail, to establish the diﬀerent stereoselectivities of
the ω-TAms used.
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Results and discussion
Our aim was to test a panel of promising and recently reported
ω-TAms against a range of functionalised cyclic ketones,
including sterically challenging substrates, to determine sub-
strate type acceptance by the selected ω-TAms. These were
(S)-ω-TAms from Chromobacterium violaceum DSM30191
(CV-TAm),37 Vibrio fluvialis (Vf-TAm),38 Klebsiella pneumoniae
KPN_0799 (Kp-TAm),39 and Pseudomonas putida PP_3718 (Pp-
TAm).36 Also the (R)-ω-TAms from Mycobacterium vanbaalenii
(Mv-TAm),40 and a variant from Arthrobacter sp. (ArRMut11).1
CV-TAm and Vf-TAm were selected as they have been used with
a range of acyclic substrates and cyclic compounds such as
cyclohexanone,19,20,31,37,38,41,42 while Pp-TAm has recently been
reported to accept dopamine36 and Kp-TAm39 was selected as a
promising TAm from screening our UCL TAm library. Mv-TAm
has been used almost exclusively with ketones/amines as
acyclic moietes,40,43,44 and ArRMut11 with 1,3-ketoamides to
generate the (R)-functionality in sitagliptin as well as for
example bicyclic tetralone and chromone substrates and a
carbazolamine.1,28,34,45
Ten ketone substrates 1–10 were selected, which would
generate the corresponding amines 1a–10a, including cyclo-
hexanone 1 and cyclopentanone 5 to determine the influence
of ring size, as well as diketones (2,6), α,β-unsaturated ketones
(4,7,9), α-tetralone 8 and ketones with α-methyl groups (3, and
camphor 10). Initial assays used the ω-TAms (crude cell
lysates) and either (R)- or (S)-α-methylbenzylamine (MBA) 11 as
the amine donor, depending on the selectivity of the trans-
aminase, with substrates 1–10: the product acetophenone was
detected by HPLC at 254 nm (Fig. 1).37 This preliminary assay
method highlighted substrates for further investigation.
Control reactions were performed in the absence of amine
acceptor and low levels of acetophenone were detected which
were subtracted from assay results with amine acceptor
present. The results indicated that several ketones showed
good levels of conversion with the ω-TAms selected, particu-
larly CV-TAm, Pp-TAm and ArRMut11. Cyclohexanone 1 was
the best cyclic substrate for most ω-TAms with conversions of
up to 40%. Interestingly, while the substitution at the α-posi-
tion on the six-membered ring in 2-methylcyclohexanone 3
was particularly well tolerated with only slightly lower conver-
sions, the presence of a conjugated CvC double bond led to
significantly less activity with 4. A similar reactivity pattern
was observed with the five-membered rings: while cyclopenta-
none 5 was readily accepted by several ω-TAms, the corres-
ponding enone 7 had negligible reactivity with all the ω-TAms
used. This presumably reflects the modified steric demands
and reactivity in the α,β-enones and less electrophilic carbonyl
moiety. The diketones 2 and 6, and bicyclic compound 10 had
negligible levels of acceptance. The bicyclic systems α-tetralone
8 (Kp-TAm, ArRMut11) and 8a-methyl-3,4,8,8a-tetrahydro-1,6-
(1H,7H)-naphthalenedione 9 were accepted with conversions at
levels of 5–10% (ArRMut11), with even lower conversions for
several of the other TAms. Tetralone 8 has previously been
used as a substrate with ArRMut11 together with co-product
removal to shift the equilibrium toward the desired amine, so
these results using two TAms and no co-product removal were
promising.28,45 The reaction of ArRMut11 with 9 has also
recently been reported, and although products were observed
by LC-MS analysis no products could be isolated.30 With the
exception of the Vf-TAm which showed in general poor activity
Fig. 1 Initial screening results giving conversions for a range of cyclic ketone substrates employing the selected ω-TAms. (R)- or (S)-MBA 11 were
used as amine donors and the product acetophenone was detected by HPLC analysis (see Scheme). All reactions were performed in triplicate and
standard deviations were less than 10%.
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with cyclic substrates, the five other ω-TAms were studied in
more detail, initially with ketone 1.
To facilitate a better comparability of the diﬀerent TAm
enzymes, the specific activity of crude cell extracts in the amin-
ation of 1 was investigated. In addition, freeze dried samples
of clarified lysate were prepared as convenient preparations for
storage and usage. The highest activity was obtained using
crude cell extracts of CV-TAm and ArRMut11, with 0.58 U mg−1
and 0.39 U mg−1 of total protein, respectively (see Experi-
mental). After lyophilisation the activity was decreased in most
cases, though not significantly, with residual activities in the
range of 55–100%. For this reason and ease of usage lyophi-
lised cell extracts were used in all of the following studies.
To identify optimal reaction conditions, as well as investi-
gating the reaction temperature and pH, a study comparing
the use of MBA 11 to both enzyme-coupled and excess amine
donor methods to shift the equilibrium towards the product
amine was conducted using cyclohexanone 1 (Scheme 1). Two
enzyme-coupled systems were used (Scheme 1a), where L- or
D-alanine was used as the amine donor and the co-product pyru-
vate was removed by either a L-lactate dehydrogenase (LDH)
(Scheme 1a A) or recycled by an alanine dehydrogenase
(AlaDH) for (S)-selective ω-TAms (Scheme 1a B).18,28,46 The
nicotinamide cofactor (NADH) required was recycled by
employing standard techniques using formate dehydrogenase
(FDH) or glucose dehydrogenase (GDH).18,28,46 An alternative
enzyme-independent method was investigated using 2-propyl-
amine (isopropylamine, IPA) 12 as the amine donor which
generates acetone as a co-product (Scheme 1b).1,37,42
Most enzymatic reactions proceeded with good conver-
sions of up to 95% (Scheme 1, Table 1), especially compared
to the conversions observed in the initial screening experi-
ments using MBA 11 (7–39%), confirming the benefits of
using shifting systems in ω-TAm reactions. Interestingly, four
of the ω-TAm reactions showed similar or higher conversions
using the IPA (12)-amine donor reaction systems compared to
the use of enzyme coupled-systems. Only the Mv-TAm showed
a slightly lower conversion (39%) compared to the AlaDH/
FDH-system (50%). In general, this broad acceptance of IPA
12 as amine donor was unexpected since IPA does not appear
to be an amine donor for many ω-TAms.47 To date, only a few
have demonstrated high tolerance towards IPA 12 such as the
engineered variant ArRMut11, and also CV-TAm which was
used in the synthesis of (2S,3S)-2-aminopentane-1,3-diol,
facilitating the use of this low cost amine donor to shift the
equilibrium towards the product.1,42 The observation that all
five of the ω-TAms investigated can be used with IPA 12 is
notable, especially with respect to the applicability of these
enzymes, due its low cost and more facile optimisation of
reaction condition since only one enzyme is required.
Moreover, the highly volatile co-product acetone can be
readily removed, as recently demonstrated in the synthesis of
sitagliptin.1
Another interesting observation was that for the Kp-TAm
and ArRMut11 no conversions were observed employing the
enzyme-coupled systems, indicating that alanine was not
accepted as an amine donor. While in engineering the Arthro-
bacter sp. ω-TAm to accept high IPA (12) and co-solvent concen-
trations the ability to use alanine has been lost, for the native
Kp-TAm enzyme not to accept alanine as an amine donor is
Scheme 1 Methods used to shift the TAm reaction equilibrium toward
the desired amine product, using 1 as the ketone acceptor. (a) Enzyme-
coupled shifted equilibrium; (b) amine donor shifted equilibrium.
Table 1 A comparison of the diﬀerent methods used to shift the equilibrium toward the product amine 1a and conversions observed after 24 h
using 1 as substrate at pH 8, 30 °C
TAm
MBA 11 amine donor
(Fig. 1) conv. (%)
A LDH/GDH
(Scheme 1a) conv. (%)
B AlaDH/FDH
(Scheme 1a) conv. (%)
IPA 12 amine donor
(Scheme 1b) conv. (%)
CV-TAm 36 92 88 94
Kp-TAm 7 0 0 22a
Pp-TAm 39 91 88 95
Mv-TAm 24 31a 50a 39a
ArRMut11 39 0 0 93
a 48 h reaction time. Reactions were performed in triplicate with standard deviations of less than 10%. Product 1a was detected by GC analysis
for methods A, B and IPA 12, and acetophenone was detected by HPLC as previously using MBA 11 as the amine donor (MBA 11 was not used in
a large excess as high numbers of equivalents have been found to have a detrimental eﬀect on the transaminase reaction).42
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unexpected. However, since Kp is a member of the Class III
transaminases and there is variable use of α-amino acids
amongst the Class III transaminases, this finding is not too
unusual.16
All further experiments were conducted using the IPA 12
shifting system because of the advantages outlined above.
The amination of 1 was then performed at two diﬀerent pHs
and temperatures typically used in transamination reactions
(Table 2). Optimal conditions which were used for further
experiments were pH 8 and 30 °C for CV-TAm and Pp-TAm, pH
8 and 45 °C for Kp-TAm and Mv-TAm, while the best con-
ditions for ArRMut11 were at pH 10 and 30 °C.
The amination of 1, 3 and 8, to give 1a, 3a and 8a was then
studied in more detail as initial experiments indicated reason-
able levels of conversion (Table 3): compound 8a is an impor-
tant chiral product and the potential to establish two
stereogenic centres in 3a in a single step is particularly inter-
esting. Ketones 1 and 3 were well accepted by the TAm
enzymes, however ketone 8 was only accepted by ArRMut11 to
give exclusively the α-aminotetraline (R)-8a, as determined by
chiral GC analysis. This was consistent with previous reports
using this ω-TAm with substrate 8.28,45 Only traces of 8a were
observed with Kp-TAm and Mv-TAm (Table 3).
Amination of the α-substituted ketone 3 involves a dynamic
kinetic resolution due to the chiral α-methyl group. Ketone 3
was accepted by all the selected ω-TAms, but conversion yields
varied from 8% to 91%. Analysis of the products by GC indi-
cated that CV-TAm preferentially gave cis-3a, while the trans-3a
isomer was formed preferentially by Pp-TAm and ArRMut11-
TAm.
A more detailed study of the amination of 3 was therefore
performed, in order to evaluate the full product stereo-
chemistry with the three most productive ω-TAms (Table 4).
Samples were taken after 2 h, 4 h, 24 h and 48 h and conver-
sions, cis : trans ratios and enantioselectivities were deter-
mined by GC analysis (Table 4). The data confirmed the
stereoselectivities observed before (Table 3), but additionally
by monitoring the amination over a period of time it became
apparent that some selectivities decreased with increasing con-
versions/time. While CV-TAm was very selective for generating
the cis-isomer the other enzymes seem to show lower selectiv-
ities. For example the ArRMut11 only showed a strong prefer-
ence towards the formation of the trans-isomer at very low
conversions (6% conversion and a cis : trans ratio of 20 : 80)
while at a conversion of 20% the cis : trans ratio had increased
to 40 : 60.
The absolute configurations of the 3a stereoisomers were
determined using known (R)- and (S)-selective TAms
(ArRMut11 and CV-TAm respectively) with (2R)-3 and racemic
3. The amine products 3a from the four reactions were then
correlated to the isomeric amine products by chiral GC-analy-
sis to establish the stereochemical outcome of the reactions.
In all cases the amine was formed in exceptionally high
stereoselectivities (>99% ee) while the variable cis : trans ratios
resulted from the ability of the ω-TAms to distinguish between
the stereocentre at the α-methyl position. Racemic samples of
3 were used in all experiments, other than when establishing
absolute configurations. For reactions where high conversions
and/or high diastereomeric ratios were observed, some racemi-
sation at the α-carbon of 3 will have occurred at pH 8 used
with CV-TAm and Pp-TAm and pH 10 with ArRMut11. Such
Table 2 The pH and temperature optimisation of the TAm reaction
using 1, and IPA 12 as the amine donor equilibrium shifting method, to
give 1a after 24 h
TAm
pH 8, 30 °C
conv. (%)
pH 8, 45 °C
conv. (%)
pH 10, 30 °C
conv. (%)
pH 10, 45 °C
conv. (%)
CV-TAm 94 91 0 n.d.
Kp-TAm 5 18 8 14
Pp-TAm 94 10 0 n.d.
Mv-TAm 17 41 7 27
ArRMut11 93 n.d. 94 90
n.d. – not determined. Conversions were determined in triplicate with
errors below 10%. Product 1a detected by GC analysis.
Table 3 ω-TAm catalysed amination of cyclic ketones 1, 3, and 8 using IPA 12 as the amine donor to give 1a, 3a, and 8a
TAm
Conv.
(%)
Conv.
(%)
Amine
config.
cis : trans
ratio
Conv.
(%)
Amine
config.
CV-TAm 94 58 (1S) 88 : 12 0 —
Kp-TAm 18 8 (1S) 63 : 37 1 n.d.
Pp-TAm 94 90 (1S) 43 : 57 0 —
Mv-TAm 41 10 (1R) 53 : 47 2 n.d.
ArRMut11 94 91 (1R) 36 : 64 19 (R)
n.d. – not determined. The reactions were performed under the optimised conditions in triplicate with a standard deviation of under 10%.
Products detected by GC and chiral GC analysis. Conversions were determined after 24 h (1a), 48 h (3a) and 144 h (8a).
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dynamic asymmetric transaminations involving α-substituted
ketones have received little attention in the literature to date.
Recently they have been described with an α-substituted
ketone possessing a large α-phenethylether group.33 However
here we have the much less sterically diﬀerentiating methyl
group at the α-position where notably for CV-TAm excellent ees
and high diastereoselectivities were observed. The change in
cis/trans product ratio over time probably reflects the consump-
tion of the prefered isomer of 3 at shorter reaction times.
Notably, for CV-TAm a high preference was observed for the
(2R)-methyl group.
In light of the high stereoselectivities for CV-TAm, docking
calculations were performed in order to gain insights into the
stereopreference observed. Calculated binding aﬃnities of all
four PLP-imine quinonoid intermediates of the reaction were
determined and results are summarised in Table 5.
Interestingly, the best calculated relative aﬃnity (∼−8 kcal
mol−1) was observed with the (R)-configured ligand, which is
preferentially transformed by the CV-TAm (Table 5, entries 1
and 2). In contrast, the minor product of the transamination
reaction (1S,2S)-3a had a lower calculated aﬃnity (−6.4 kcal
mol−1, entries 3 and 4). Thus the trend generally matched the
observed experimental data. For more insights, both equatorial
quinonoid intermediates (R)-(entry 1) and (S)-(entry 3) were
evaluated in more detail after modelling into the active site
using the holo structure of CV-TAm (4AH3).48 As shown in
Fig. 2, the position of the six-membered ring varied depending
on the methyl group stereochemistry. Moreover, the docked
structures show that the (2R)-quinonoid (green), better fits the
space available in the binding pocket (indicated in grey).
Table 4 Transamination of 3 to 3a-isomers using IPA 12 as the amine donor, and conversions, cis : trans ratios and ees over a reaction time of 48 h
TAm Time (h) Conv. (%)
CV-TAm 2 23 96 : 4
4 33 93 : 7 All All
24 47 88 : 12 >99 (1S,2R) >99 (1S,2S)
48 58 88 : 12
Pp-TAm 2 31 61 : 36
4 49 54 : 46 All All
24 90 42 : 58 >99 (1S,2R) >99 (1S,2S)
48 90 43 : 57
ArRMut11 2 6 20 : 80
4 20 40 : 60 All All
24 76 38 : 62 >99 (1R,2S) >99 (1R,2R)
48 91 36 : 64
Conversions and cis : trans ratios were detected by achiral GC, while ee-values were determined using chiral GC; results were determined in
triplicate with a standard deviation of less than 10%.
Table 5 Calculated relative binding aﬃnities of the quinonoid inter-
mediates (with the methyl group both axial and equatorial)
Entry
Configuration
(methyl)a
Final conformation
of methyl group
Relative binding
aﬃnity (kcal mol−1)
1 R Equatorial −8.1
2 R Axial −7.9
3 S Equatorial −6.4
4 S Axial −6.4
a The PLP structure in the docking experiments was overlayed with the
PLP as reported in the crystal structure.
Fig. 2 Docking of (2S) (pink) and (2R) (green) quinonoid intermediate
into the active site of CV-TAm (4AH3). The binding pocket is indicated as
grey shadow, and amino acids involved in the transamination reaction
are labelled.
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However, apart from slightly better positioning of the (2R)- vs.
the (2S)-quinonoid no additional steric factors could be deter-
mined to explain the stereochemistries observed. In general,
the residue Lys288 is known to play a crucial role in the cata-
lytic mechanism of TAms.48,49 When no substrate is in the
active site it forms a Schiﬀs base with the PLP cofactor, and
during the reaction the amine donor replaces the Lys288,
which is released as a consequence and changes its position.
It is therefore possible that the dynamic repositioning of
Lys288 further influences the stereopreference observed.
Conclusions
Several (S)- and (R)-ω-transaminases have been investigated for
the transamination of a range of cyclic ketones. In a prelimi-
nary screen suitable TAms were identified to transform the
substrates of interest and the amine donor 2-propylamine 12
was accepted by all five selected ω-TAms for further study. The
amination of cyclohexanone 1, 2-methylcyclohexanone 3, and
α-tetralone 8 were studied in more detail: yields of up to 94%
were achieved with selected transaminases. When using
2-methylcyclohexanone 3 enantio- and diastereoselectivities
were investigated. The highest selectivities were obtained when
using CV-TAm: (1S)-2-methylcyclohexylamine was formed with
complete selectivity at the amine position and up to 24 : 1
diastereoselectivity for the cis (1S,2R) isomer. This high reac-
tion selectivity is extremely interesting as it enables the cyclic
amine 3a containing two-defined chiral centres to be formed
in one step from racemic starting material. Such dynamic
asymmetric transaminations with α-ketones have received little
attention to date, and the high selectivities achieved by
CV-TAm with α-substituted substrates will be explored in
future work with CV-mutants.
Experimental
General
All starting materials were obtained from commercial suppli-
ers and used as received unless otherwise stated. DNA-modify-
ing enzymes were obtained from Thermo scientific (Germany)
or New England Biolabs (USA). The enzymes used for shifting
the equilibrium were commercially available from: L-lactate
dehydrogenase from rabbit muscle (Sigma-Aldrich, Austria),
glucose dehydrogenase (X-zyme, Germany), and formate de-
hydrogenase from Candida boidinii (Codexis, USA). The L-alanine
dehydrogenase was prepared as reported previously.46 (R)- and
(S)-8a are commercially available. (R)-3 was prepared as pre-
viously described.50
Cloning of TAm genes in suitable expression vectors
A synthetic gene for the previously reported ω-TAm from
Arthrobacter sp. variant (ArRMut11)1 was designed, as codon-
optimised genes (DNA 2.0, U.S.A.), and subsequently cloned
into the expression vector pET29a (Invitrogen, Germany) using
standard techniques. Additionally, plasmids containing
codon-optimised genes of the ω-TAms from Chromobacterium
violaceum,37 Vibrio fluvialis,38 Pseudomonas putida (Pp-TAm),36
and Klebsiella pneumoniae39 were used. In addition, the ω-TAm
from Mycobacterium vanbaalenii Mvan4516 (Mv-TAm) (gene
bank accession no. 119958286; ABM15291)40 was amplified
from genomic DNA using the primers listed below and stan-
dard PCR procedures. Restriction sites were introduced to
enable the cloning in the desired expression vector pET29a
(Table 6).
Heterologous enzyme expression and preparation
The ω-TAms from Chromobacterium violaceum and Vibrio fluvia-
lis were expressed as described previously.37,38 All other
ω-TAms were expressed in E. coli BL21(DE3)pLysS in lysogeny
broth medium containing ampicillin (100 mg L−1). Cultures
were grown at 37 °C until an OD600 of 0.5-0.7 was reached.
Enzyme expression was induced by addition of isopropyl-β-D-
thiogalactopyranoside (0.5 mM), and the temperature was
reduced to 25 °C. After 16–20 h cells were harvested by cen-
trifugation and stored at −20 °C. To prepare cell free crude
extract cells (20% v/w) were suspended in HEPES buﬀer
(100 mM, pH 7.5) containing pyridoxal-5-phosphate (PLP)
(0.5 mM), and disrupted by ultra sonication (2 × 1 min, 40%
output). The crude extract was cleared by centrifugation
(20 min, 16.000g) and either directly used or freeze dried and
stored at −20 °C.
General procedure for TAm screening
For the HPLC-based TAm screening (R)- or (S)-α-methyl-
benzylamine (MBA) 11 (25 mM) and pyridoxal-5-phosphate
(PLP) (0.5 mM) were dissolved in HEPES buﬀer (100 mM, pH
8). E. coli crude extract (12.5 μL) containing the overexpressed
ω-TAm were added to 212.5 μL of this solution. The reaction
was started by the addition of 25 μL of substrate in DMSO
(final concentration 10 mM, 10 vol%). After an incubation for
21 h at 30 °C and 180 rpm the reaction was stopped by the
addition of 250 μL of acetonitrile containing 0.2% TFA. De-
naturated protein was removed by centrifugation, and the super-
natant was analysed by HPLC (Agilent) using a Discovery®Bio
Wide Pore C18 column (Supelco, 25 × 4.6 mm, 10 µm beads)
Table 6 Sequence of the primers used for the ampliﬁcation of Kp-TAm
and Mv-TAm
Name Sequence
Restriction
site
Kp_forward ACACTGGACGATCTCGC NdeI
Kp_reverse TTCGCTAAAAAATGTTTC XhoI
Mv_forward ATATA GGCATTG
ACACCGGAACCTCGAATCTC
NdeI
Mv_reverse ATA TCAG
TACTGGATCGCTTCGATCAG
NotI
Restriction sites used for cloning are underlined.
Paper Organic & Biomolecular Chemistry
8848 | Org. Biomol. Chem., 2015, 13, 8843–8851 This journal is © The Royal Society of Chemistry 2015
with UV detection at 254 nm. Concentrations of acetophenone
were determined using a linear gradient: 30%–60% B over
10 min (A = water, B = acetonitrile, both containing 0.1% TFA).
The acetophenone produced eluted at a retention time of
8.6 min.
Determination of initial rates of the five selected TAms
Initial rates were determined using the HPLC-based method
described above using cyclohexanone 1 as the substrate. Cyclo-
hexanone (10 mM), (R)- or (S)-MBA 11 (10 mM) and PLP
(1 mM) were solved in sodium phosphate buﬀer (100 mM, pH
8). The reaction was started by addition of 100 μL of enzyme
solution (crude cell extract or freeze dried cells). Samples were
taken after 5 min, 10 min, 15 min, and 30 min, and the linear
slope was used for the calculation of initial rates and specific
activities (Table 7).
General procedure for the TAm reactions using diﬀerent
equilibrium shifting systems
Transamination reactions using the (a) AlaDH/FDH, (b) LDH/
GDH or (c) 2-propylamine IPA 12 system were performed as
follows: (a) substrate (20 mM), D- or L-alanine (200 mM),
ammonium formate (60 mM), PLP (1 mM), NAD+ (0.5 mM),
formate dehydrogenase (11 U) and L-alanine dehydrogenase
(12 U) were dissolved in sodium phosphate buﬀer (1 mL,
100 mM, pH 8); (b) substrate (20 mM), D- or L-alanine
(200 mM), glucose (60 mM), PLP (1 mM), NAD+ (0.5 mM),
glucose dehydrogenase (30 U) and L-lactate dehydrogenase (90
U) were dissolved in sodium phosphate buﬀer (1 mL, 100 mM,
pH 8); (c) substrate (20 mM), IPA 12 (200 mM), and PLP
(1 mM) were dissolved in sodium phosphate buﬀer (1 mL,
100 mM, pH 8 or 10). All biotransformations were started by
the addition of lyophilised E. coli crude cell extract containing
the overexpressed ω-TAm corresponding to an activity of 0.5 U
in the amination of cyclohexanone (CV-TAm, Pp-TAm and
ArRMut11 see Table 1), while the maximum amount of 10 mg
was added in the case of the Kp-TAm and Mv-TAm. The
mixture was incubated at 30 °C or 45 °C and 800 rpm in a
thermoshaker (Eppendorf, Germany).
Samples were taken at diﬀerent time points, and the reac-
tion was stopped by addition of 10 vol% of NaHCO3, and
extracted with ethyl acetate (2 × 500 μL). Conversions to the
amine were measured by GC (Agilent 7890 A system equipped
with a FID detector). The biotransformations of cyclohexanone
1 and 2-methylcyclohexanone 3 were monitored using an
Agilent DB-1701 column (30 m, 0.25 mm, 0.25 μm) using the
following temperature programmes: A 60 °C, hold for 5 min,
15 °C min−1 to 150 °C; retention times cyclohexylamine 1a
6 min and cyclohexanone 1 7.9 min. B 60 °C, hold for 5 min,
5 °C min−1 to 80 °C, 60 °C min−1 to 250 °C; retention times
trans-3a 5.9 min, cis-3a 6.4 min and 3 8.4 min. Conversions for
α-tetralone 8 were determined using an Agilent HP5 (30 m,
0.32 mm, 0.25 μm) and the following programme: 120 °C,
5 °C min−1 to 160 °C, 50 °C min−1 to 300 °C, retention times
1-aminotetraline 8a 4.4 min and α-tetralone 8 4.7 min.
Determination of enantiomeric purity
The enantiomeric exessess of amines 3a and 8a were deter-
mined by GC using a modified β-cyclodextrin column
(CP-Chirasil-DEX CB, 25 m, 0.32 mm, 0.25 μm) after derivatisa-
tion to the corresponding trifuoroacetamides. For the derivati-
sation trifluoroacetic anhydride (5 μL) was added to the
extracted sample, and after an incubation (800 rpm) at 30 °C
the reaction was quenched with NaHCO3 and the ee was ana-
lysed. Temperature programme for 3a: 100 °C hold 2 min, 2 °C
min−1 to 135 °C, 25 °C min−1 to 180 °C. Retention times:
(1S,2R)-3a 5.5 min, (1R,2S)-3a 5.7 min, (1S,2S)-3a 6.7 min and
(1R,2R)-3a 7 min. Temperature programme for 8a: 120 °C, 5 °C
min−1 to 160 °C, 20 °C min−1 to 180 °C. Retention times:
(S)-8a 8.2 min and (R)-8a 8.5 min.
Docking studies
For docking experiments the holo crystal structure of the
ω-TAm from C. violaceum was used (pdb: 4AH3). The apo-struc-
ture of 4AH3 as well as the structure of the quinonoid inter-
mediate51 of all conformers were generated with Maestro and
the energy optimisation of the ligands was performed using
the MacroModel “Minimization” followed by a “Conformation-
al Search” (all Schrödinger LLC). The two conformations with
the lowest energy were used for the docking experiments.
Optimisation of the protein structure after removal of the
bound PLP was performed with autodock tools v 1.5.6.
Docking calculations were performed using AutoDock Vina52
with a x = 24/y = 24/z = 24 grid box centred on x = 4.8, y = −0.5,
z = 7.4. Lowest energy clusters were selected and visualised
using pymol v0.99rc6.
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Table 7 Speciﬁc activities of selected TAms using cyclohexanone 1 as
substrate and (R)- or (S)-MBA 11 as amine donor
TAm
Crude cell extract
[U mg−1 total protein]
Freeze dried cell extract
[U mg−1 total protein]
CV-TAm 0.58 0.32
Kp-TAm n.d. 0.008
Pp-TAm 0.13 0.11
Mv-TAm 0.006 0.006
ArRMut11 0.39 0.24
n.d. – not determined.
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